Riskpilot← Back to searchSign inGet full accessSynapticon AB
ABActiveOrg 5591876437Dag Hammarskjölds Väg 3 BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20181 employees
Revenue 2025
SEK 1,4M
-58% vs 2024
EBITDA margin
-7.0%
-105% vs 2024
Equity ratio
67.6%
Financial strength
Net profit 2025
SEK -42K
-104% vs 2024
| Revenue | SEK 1,4M | -58% |
| EBITDA | SEK -96K | -105% |
| Net profit | SEK -42K | -104% |
| Total assets | SEK 4,6M | -11% |
| Equity | SEK 3,1M | -16% |
| Employees | 1 | — |
Legal name
Synapticon AB
Org number
5591876437
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19 december 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-02-28
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
1) Konsultverksamhet inom klinisk cancerforskning, radionuklidterapi och endokrin onkologi 2) Hyrläkarverksamhet 3) Medical writing 4) Konsultverksamhet inom affärsutveckling inom molekylär biologi, diagnostik och bioteknik
Address
Dag Hammarskjölds Väg 3 B
Email
juan.bataller@synapticon.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 938 | 2 549 | 2 631 | 3 248 | 1 372 |
| Staff expenses | — | −1 050 | −898 | −997 | −932 |
| EBITDA | 1 596 | 1 249 | 1 408 | 1 885 | −96 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 1 596 | 1 249 | 1 408 | 1 885 | −96 |
| Net financials | — | −1 | −0 | 9 | 54 |
| Profit before tax | 1 295 | 938 | 1 055 | 1 412 | −42 |
| Tax | −277 | −194 | −223 | −300 | — |
| Net profit | 1 018 | 744 | 831 | 1 113 | −42 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 738 | 2 786 | 3 783 | 5 226 | 4 636 |
| Equity | 1 140 | 1 884 | 2 715 | 3 728 | 3 136 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 299 | 292 | 105 | 54 | 55 |
| Total debt | 299 | 292 | 105 | 54 | 55 |
EBITDA margin
-7.0%
This company
15.8%
Market median
-144% vs market
20212025
Equity ratio
67.6%
This company
38.2%
Market median
+77% vs market
20212025
Return on equity
-1.3%
This company
18.4%
Market median
-107% vs market
20212025
Net profit margin
-3.1%
This company
8.1%
Market median
-138% vs market
20212025
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20212025
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-03-01 – 2025-02-28
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-03-01 – 2024-02-29
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-03-01 – 2023-02-28
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-02-28
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-02-28
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Synapticon AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Juan Antonio Bataller | Board of Directors | 0 companies |
| Anna Birgitta Sundlöv | Board of Directors | 0 companies |
| Paula Bataller Sundlöv | Deputy Board Member | 0 companies |